BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. We target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
Our team consists of experienced investment professionals with extensive expertise in investing and building healthcare companies. In addition, our team is supported by a dedicated team of seasoned senior scientific and business advisors and has access to a broad network within academia, finance and industry. We take an active role in the development of our portfolio companies as a lead investor or as an active syndicate partner.
Currently, BioMedPartners manages two investment vehicles, BioMedInvest I (with BioMedCredit) and BioMedInvest II with a total capital under management of CHF 250 million. Both funds invest in innovative early- to mid-stage companies that have the potential to achieve exceptional growth driven by novel technologies, products or services with unique advantages over current treatments.
Based in Basel, BioMedPartners has successfully invested in more than 45 human life science companies over the last ten years, of which a large number has already listed on the stock exchange or has been acquired by leading players in the pharmaceutical industry.
BioMed's investors represent leading international enterprises and institutions.